Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Summaries of opinion (7) Apply Summaries of opinion filter Withdrawn applications (7) Apply Withdrawn applications filter Orphan designations (39) Apply Orphan designations filter Direct healthcare professional communication (6) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (150) Apply Authorised filter Refused (2) Apply Refused filter Withdrawn (34) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (5) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (37) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (10) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (18) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (5) Apply European Commission final decision filter

Referral safety status

Yes (1) Apply Yes filter

Referral type

Article 20 procedures (4) Apply Article 20 procedures filter Article 31 referrals (1) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (3) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (1) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (4) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (4) Apply Risk minimisation measures filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Exceptional circumstances Remove Exceptional circumstances filter Additional monitoring (579) Apply Additional monitoring filter Conditional approval (80) Apply Conditional approval filter Generic (325) Apply Generic filter Orphan medicine (255) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

245 results

Remove all filtersRemove all filters

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Medicine Referrals Remove Referrals filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Sort by

List item

Human medicine European public assessment report (EPAR): Zessly

infliximab, Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing
Date of authorisation: 18/05/2018, , Revision: 11, Authorised, Last updated: 14/07/2023
List item

Human medicine European public assessment report (EPAR): Zercepac

trastuzumab, Breast Neoplasms; Stomach Neoplasms
Date of authorisation: 27/07/2020, , , Revision: 9, Authorised, Last updated: 11/07/2023
List item

Human medicine European public assessment report (EPAR): Praxbind

idarucizumab, Hemorrhage
Date of authorisation: 20/11/2015, , Revision: 12, Authorised, Last updated: 11/07/2023
List item

Human medicine European public assessment report (EPAR): Insulin lispro Sanofi

insulin lispro, Diabetes Mellitus
Date of authorisation: 19/07/2017, , Revision: 9, Authorised, Last updated: 07/07/2023
List item

Human medicine European public assessment report (EPAR): Insulin aspart Sanofi

insulin aspart, Diabetes Mellitus
Date of authorisation: 25/06/2020, , Revision: 4, Authorised, Last updated: 07/07/2023
List item

Human medicine European public assessment report (EPAR): Truvelog Mix 30

insulin aspart, Diabetes Mellitus
Date of authorisation: 25/04/2022, , , Revision: 2, Authorised, Last updated: 06/07/2023
List item

Human medicine European public assessment report (EPAR): Bekemv

Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 19/04/2023, , Revision: 1, Authorised, Last updated: 06/07/2023
List item

Human medicine European public assessment report (EPAR): Bylvay

Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021, , , , Revision: 3, Authorised, Last updated: 05/07/2023
List item

Human medicine European public assessment report (EPAR): Livmarli

Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022, , , , Revision: 2, Authorised, Last updated: 05/07/2023
List item

Human medicine European public assessment report (EPAR): Kalydeco

ivacaftor, Cystic Fibrosis
Date of authorisation: 23/07/2012, , Revision: 36, Authorised, Last updated: 30/06/2023
List item

Human medicine European public assessment report (EPAR): Myalepta

Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018, , , , Revision: 8, Authorised, Last updated: 29/06/2023
List item

Human medicine European public assessment report (EPAR): Cabometyx

cabozantinib (s)-malate, Carcinoma, Renal Cell; Carcinomas, Hepatocellular
Date of authorisation: 09/09/2016, , Revision: 17, Authorised, Last updated: 23/06/2023
List item

Human medicine European public assessment report (EPAR): Ximluci

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 09/11/2022, , , Revision: 1, Authorised, Last updated: 20/06/2023
List item

Human medicine European public assessment report (EPAR): Vidaza

azacitidine, Myelodysplastic Syndromes
Date of authorisation: 17/12/2008, , Revision: 26, Authorised, Last updated: 15/06/2023
List item

Human medicine European public assessment report (EPAR): Defitelio

defibrotide, Hepatic Veno-Occlusive Disease
Date of authorisation: 18/10/2013, , , , Revision: 15, Authorised, Last updated: 15/06/2023
List item

Human medicine European public assessment report (EPAR): Lojuxta

Lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013, , , Revision: 17, Authorised, Last updated: 14/06/2023
List item

Human medicine European public assessment report (EPAR): Maviret

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , Revision: 22, Authorised, Last updated: 09/06/2023
List item

Human medicine European public assessment report (EPAR): Upstaza

Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022, , , , Revision: 5, Authorised, Last updated: 09/06/2023
List item

Human medicine European public assessment report (EPAR): Onpattro

patisiran sodium, Amyloidosis, Familial
Date of authorisation: 27/08/2018, , , , Revision: 11, Authorised, Last updated: 02/06/2023
List item

Human medicine European public assessment report (EPAR): Oxervate

Recombinant human nerve growth factor, Keratitis
Date of authorisation: 06/07/2017, , , , Revision: 2, Authorised, Last updated: 02/06/2023
List item

Human medicine European public assessment report (EPAR): Empliciti

Elotuzumab, Multiple Myeloma
Date of authorisation: 11/05/2016, , Revision: 12, Authorised, Last updated: 01/06/2023
List item

Human medicine European public assessment report (EPAR): Epysqli

Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 26/05/2023, , , Authorised, Last updated: 31/05/2023
List item

Human medicine European public assessment report (EPAR): Ratiograstim

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 15/09/2008, , Revision: 16, Authorised, Last updated: 30/05/2023
List item

Human medicine European public assessment report (EPAR): Evoltra

clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 29/05/2006, , , Revision: 33, Authorised, Last updated: 25/05/2023
List item

Human medicine European public assessment report (EPAR): Nivestim

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 07/06/2010, , Revision: 27, Authorised, Last updated: 23/05/2023

Load more

245 results

Human medicine European public assessment report (EPAR): Zessly

Human medicine European public assessment report (EPAR): Zercepac

Human medicine European public assessment report (EPAR): Praxbind

Human medicine European public assessment report (EPAR): Insulin lispro Sanofi

Human medicine European public assessment report (EPAR): Insulin aspart Sanofi

Human medicine European public assessment report (EPAR): Truvelog Mix 30

Human medicine European public assessment report (EPAR): Bekemv

Human medicine European public assessment report (EPAR): Bylvay

Human medicine European public assessment report (EPAR): Livmarli

Human medicine European public assessment report (EPAR): Kalydeco

Human medicine European public assessment report (EPAR): Myalepta

Human medicine European public assessment report (EPAR): Cabometyx

Human medicine European public assessment report (EPAR): Ximluci

Human medicine European public assessment report (EPAR): Vidaza

Human medicine European public assessment report (EPAR): Defitelio

Human medicine European public assessment report (EPAR): Lojuxta

Human medicine European public assessment report (EPAR): Maviret

Human medicine European public assessment report (EPAR): Upstaza

Human medicine European public assessment report (EPAR): Onpattro

Human medicine European public assessment report (EPAR): Oxervate

Human medicine European public assessment report (EPAR): Empliciti

Human medicine European public assessment report (EPAR): Epysqli

Human medicine European public assessment report (EPAR): Ratiograstim

Human medicine European public assessment report (EPAR): Evoltra

Human medicine European public assessment report (EPAR): Nivestim